A liquid mixed meal or exogenous glucagon-like peptide 1 (GLP-1) do not alter plasma leptin concentrations in healthy volunteers

Acta Diabetologica

Volumn 34, Issue 3, 1997, Pages 230-234

  Drewes, C ^a   Nauck, M A ^a   Horn, R ^b   Holst, J ^c   Schmiegel, W ^a   Brabant, G ^b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

C peptide; Glucagon like peptide 1; Leptin; Obesity

Indexed keywords

AMINO ACID; CREATININE; GENE PRODUCT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LEPTIN; SUCROSE;

ADULT; ARTICLE; BLOOD LEVEL; BRAIN FUNCTION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEEDING; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; INTRAVENOUS DRUG ADMINISTRATION; NORMAL HUMAN; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; REGULATORY MECHANISM; STATISTICAL ANALYSIS; TEST MEAL;

ADULT; BLOOD GLUCOSE; FOOD, FORMULATED; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INFUSIONS, INTRAVENOUS; INSULIN; LEPTIN; PEPTIDE FRAGMENTS; POSTPRANDIAL PERIOD; PROTEIN PRECURSORS; PROTEINS; TIME FACTORS;

EID: 0030666310     PISSN: 09405429     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005920050079     Document Type: Article

References (47)

1. Zhang Y, Proenca P, Maffei M, Barone M, Leopold L, Friedmann JM, Positional cloning of the mouse obese gene and its human homologue. Nature 372:425-432, 1994
2. Halaas JL, Gajiwala KS, Maffei M, Cohen S, Chait BT, Rabiowitz D, Lallone RL, Burley KS, Friedman JM, Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269:543-546, 1995
3. Pelleymounter M, Cullen M, Baker M, Hecht R, Winters D, Bone T, Collins F, Effects of the obese gene product on body weight regulation in ob/ob mice. Science 269:540-543, 1995
4. Levin N, Nelson C, Gurney A, Vandlen R, DeSauvage F, Decreased food intake does not completely account for adiposity reduction after ob protein infusion. Proc Natl Acad Sci USA 93:1726-1730, 1996
5. Tartaglia LA, Demski M, Weng X, Deng N, Culpepper J, Devos R, Richards JG, Campfield LA, Clark FT, Deeds J, Muir C, Sanker S, Moriaty A, Moore KJ, Smutko JS, Mays GG, Woolf CA, Monroe CA, Tepper RI, Identification and expression cloning of a leptin receptor (OB-R). Cell 83:1263-1271, 1995
6. Stephens TW, Basinski M, Bristow PK, Bue-Valleskey JM, Burgett SG, Craft L, Hale J, Hoffmann J, Hsiung HM, Kriauciunas A, MacKellar W, Rosteck PR, Schoner B, Smith D, Tinsley FC, Zhang X-Y, Heiman M, The role of neuropeptide Y in the anti-obesity action of the obese gene product. Nature 377:530-532, 1995
7. Vettor R, Zarjevski N, Cusin I, Rohner-Jeanrenaud F, Jeanrenaud B, Induction and reversibility of an obesity syndrome by intracerebroventricular neuropeptide Y administration to normal rats. Diabetologia 37:1202-1208, 1994
8. Dryden S, Frankish H, Qiong W, Williams G, Neuropeptide Y and energy balance one way ahead for the treatment of obesity? Eur J Clin Invest 24:293-308, 1994
9. Sainsbury A, Cusin I, Doyle P, Rohner- Jeanreaud F, Jeanreaud B, Intracerebroventricular administration of neuropeptide Y to normal rats increases obese gene expression in white adipose tissue. Diabetologia 39:353-356, 1995
10. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CMB, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JPH, Smith DM, Ghatei MA, Herbert J, Bloom SR, A role for glucagon-like peptide 1 in the central regulation of feeding. Nature 379:69-72, 1996
11. Göke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Göke B, Exendin-4 is a high potency agonist and truncated exendin-[9-39]-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-ceils. J Biol Chem 268:19650-19655, 1993
12. Thorens B, Poerret A, Buhler L, Deng SP, Morel P, Widman C, Cloning and functional characterization of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) is an antagonist of the receptor. Diabetes 42:1678-1682, 1993
13. Meeran K, O'Shea D, Truton M, Heath M, Gunn I, Choi SJ, Edwards M, Small C, Ghatei M, Bloom SR, Chronic blockade of hypothalamic glucagon-like peptide 1 receptors causes obesity Diabetes 45 [Suppl 2]:622, 1996
14. Ørskov C, Tang-Christiansen M, Holst JJ, Larsen PJ, Distribution of glucagon-like peptide 1 and other preproglucagon derived peptides in the rat hypothalamus and brain stem. Diabetes 45 [Suppl 2]:546, 1996
15. Devos R, Richards JG, Campfield LA, Tartaglia LA, Guisez Y, Van der Heyden J, Travernier J, Plaetnick G, Burn P, OB protein binds specifically to the choroid plexus of mice and rats. Proc Natl Acad Sci USA 93:5668-5673, 1996
16. 2 binding sites in rat brain (abstract). Digestion 46 [Suppl 1]:104, 1991
17. Shimizu I, Hirota M, Ohboshi C, Shima K, Identification and localization of glucagon-like peptide-1 and its receptor in rat brain. Endocrinology 121:1076-1082, 1987
18. Ørskov C, Poulsen SS, Møller M, Holst JJ, Glucagon-like peptide 1 receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide 1. Diabetes 45:832-835, 1996
19. Wettergren A, Petersen H, Ørskov C, Christiansen J, Sheikh SP, Holst JJ, Glucagon-like-peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. Scand J Gastroenterol 29:501-505, 1994
20. Ritzel R, Ørskov C, Holst JJ, Nauck MA, Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response relationships. Diabetologia 38:720-725, 1995
21. Valverde I, Mérida E, Delgado E, Trapote MA, Villanueva-Peñcarillo ML. Presence and characterization of GLP-1 receptors in solubilized membranes of rat adipose tissue. Endocrinology 132:75-77, 1993
22. Mérida E, Delgado E, Molina LM, Villanueva-Peñcarillo MLM, Valverde I, Presence of glucagon and glucagon-like peptide-I-(7-36)-amide receptors in solubilized membranes from human adipose tissue. J Clin Endocrinol Metab 77:1654-1657, 1993
23. Egan JM, Montrose-Rafizadeh C, Wang Y, Bernier M, Roth J, Glucagon-like peptide-I-(7-36)-amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. Endocrinology 135:2070-2075, 1994
24. Oben J, Morgan J, Fletcher J, Marks V, Effect of the enteropancreatic hormones gastric inhibitory polypeptide and glucagon-like peptide-1(7-36)amide, on fatty acid synthesis in explants of rat adipose tissue. J Endocrinol 130:267-272, 1991
25. Saladin R, De Vos P, Guerre-Millo M, Leturque A, Girard J, Steals B, Auwerx J, Transient increase in obese gene expression after food intake or insulin administration. Nature 377:527-529, 1995
26. Mizuno TM, Bergen H, Funabashi T, Kleopoulos SP, Zhong YG, Bauman WA, Mobbs CV, Obese gene expression: reduction by fasting and stimulation by insulin and glucose in lean mice, and persistent elevation in acquired (diet-induced) and genetic (yellow agouti) obesity. Proc Natl Acad Sci USA 93:3434-3438, 1996
27. Malmström R, Taskinen M-R, Karonen S-L, Yki-Järvinen H, Insulin increases plasma leptin concentrations in normal subjects and patients with NIDDM. Diabetologia 39:993-996, 1996
28. Vidal H, Auboeuf D, De Vos P, Staels B, Riou JP, Auwerx J, Laville M, The expression of ob gene is not acutely regulated by insulin and fasting in human abdominal subcutaneous adipose tissue. J Clin Invest 98:251-255, 1996
29. Drewes C, Nauck MA, Horn R, Niedereichholz U, Ettler R, Holst JJ, Schmiegel W, Brabant G, A liquid meal or exogenous GLP-1 do not alter plasma leptin concentrations in healthy volunteers (abstract). Diabetologia 39 [Suppl 1]:540, 1996
30. Willms B, Werner J, Ørskov C, Holst JJ, Creutzfeldt W, Nauck M, Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in Type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81:327-332, 1996
31. Nauck MA, Blietz RW, Qualmann C, Comparison of hyperinsulinaemic clamp experiments using venous, 'arterialized' venous or capillary euglycaemia. Clin Physiol 16: 589-602, 1996
32. Kreymann B, Ghatei MA, Williams G, Bloom SR, Glucagon-like peptide 1 7-36: a physiological incretin in man. Lancet II: 1300-1304, 1987
33. Nauck M, Bartels E, Ørskov C, Ebert R, Creutzfeld W, Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7-36 amide] infused at near physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76:912-917, 1993
34. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W, Preserved incretin activity of glucagon-like peptide 1 (GLP-1) [7-36 amide] but not of synthetic human gastric inhibitory polypeptide (GIP) in patients with Type 2 diabetes mellitus. J Clin Invest 91:301-307, 1993
35. Ørskov C, Holst JJ, Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand J Clin Lab Invest 47:165-174, 1987
36. Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ, Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes 43:535-539, 1994
37. Horn R, Geldszus, Pötter E, Mühlen A von zur, Brabant G, Radioimmunoassay for the detection of leptin in human serum. Exp Clin Endocrinol Diabetes 104:454-458, 1997
38. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Ørskov C, Schmiegel WH, Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy volunteers. Am J Physiol (in press), 1997
39. Sinha MK, Ohannesian JP, Heiman ML, Kriauciunas A, Stephans TW, Magosin S, Marco C, Caro FJ, Noctural rise of leptin in lean, obese, and non-insulin- dependent diabetes mellitus subjects. J Clin Invest 97:1344-1347, 1996
40. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V, Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 138:159-166, 1993
41. Teff K, Mattes RD, Engelman K, Cephalic phase insulin release in normal weight males: verification and reliability. Am J Physiol 261:E430-435, 1991
42. Ahima RS, Prabakaran, D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E, Flier JS, Role of leptin in the neuroendocrine response to fasting. Nature 382:250-252, 1996
43. Mohamed-Ali V, Klein S, Landt M, Coppack SW, Adipose tissue leptin production and plasma leptin kinetics in humans. Diabetologia 39 [Suppl 1]:A542, 1996
44. Kolacynski JW, Ohannesian JP, Considine RV, Marco CC, Caro JF, Response of leptin to short-term and prolonged overfeeding in humans. J Clin Endocrinol Metab 81:4162-4165, 1996
45. Toft-Nielsen M, Madsbad S, Holst JJ, The effect of glucagon-like peptide 1 (GLP-1) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 45:552-556, 1996
46. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephans TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF, Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334:292-295, 1996
47. Havel PJ, Kasim-Karakas S, Mueller W, Johnson PR, Gingerich RL, Stern JS, Relationship of plasma leptin to plasma insulin in adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss. J Clin Endocrinol Metab 81:4406-4413, 1996